CABA Cabaletta Bio Inc: מקדם חוב לטווח ארוך להון

The confirmed price history on the Cabaletta Bio, Inc. (CABA) chart unfolds within a stable US legal framework, where developments are protected by international humanitarian law. Cabaletta Bio, Inc. (CABA) revenues are based on the implementation of CART-cell therapy against severe autoimmune pathologies. The business also relies on exclusive patents in the field of skin disease treatment, which ensures the uniqueness of its offerings. The current indicator is 0.03.

Conservative capital demands transparency regarding debt loads to assess business resilience to systemic shocks. This indicator correlates liabilities with maturities exceeding one year against equity, determining the degree of financial leverage and dependence on borrowed funds. Amid FDA regulatory risks and threats of CAR-T therapy side effects, the long-term debt-to-equity chart confirms the margin of safety for Cabaletta Bio, Inc. (CABA).